How to Develop Global Clinical Evidence Strategies for Regulatory Success in Medtech

Clinical evidence generated in one market can often support regulatory submissions in others when it has been designed with international expectations in mind. Regulators expect robust evidence that demonstrates safety and performance, and each jurisdiction applies its own regulatory framework and assesses data generated in other markets against its own clinical practice, standard of care, and regulatory precedents.

Evidence strategies that do not consider future markets can create additional work, increase development costs, and delay patient access. How can medical device manufacturers maximize the global value of their clinical evidence? This article outlines the key factors regulators consider when it comes to device approval, the evidence most likely to be accepted across jurisdictions, and the best regulatory practices for international expansion.

When to Build Your Clinical Evidence-Generation Plan for Future Markets

Medtech companies with international commercialization ambitions should begin clinical evidence planning as early as product development allows. A proactive plan can significantly reduce future development timelines, costs, and regulatory risk. The objective of a good plan is to identify and understand future regulatory and clinical requirements specific to your product and markets early enough to make informed development decisions.

Consideration of country-specific regulatory requirements early helps manufacturers avoid generating evidence that is difficult or impossible to leverage in later submissions. Early planning also provides greater flexibility to adapt overall clinical development as requirements expand or change.

Potential steps in building an evidence strategy include:

• Identify country-specific differences early so they can be addressed through future studies or bridging strategies that avoid market expansion delays
• Consider additional secondary endpoints that may be valuable for future submissions
• Develop a real-world evidence strategy capable of complementary clinical evidence generation for additional markets

How to Design Integrated Global Evidence Strategies for Approval in Your Target Markets

Successful global commercialization strategy begins with a clear regulatory strategy that then influences the clinical development plan for your product. Manufacturers must first define the priority target markets and perform a comprehensive assessment of regulatory requirements across those jurisdictions before they define the specificities and finalize the clinical development plan. This clear and early picture of regional requirements allows manufacturers to proactively address evidence gaps rather than discover them during preparation for future submissions.

Manufacturers can then identify common evidence requirements that support multiple submissions simultaneously and highlight regional differences early. It is important to determine whether these differences should be addressed within the initial clinical program or through complementary approaches such as real-world evidence, bridging studies, or post-market clinical follow-up.

Finally, manufacturers should maintain regular dialogue with regulatory authorities throughout development and establish clear regional priorities if commercial or development priorities change over time.

Manufacturers need to focus on their prioritized markets and design a core integrated global evidence strategy that considers shared regulatory expectations while maintaining sufficient flexibility to address local requirements where necessary.

What Determines Evidence Acceptance Abroad

When medtech companies leverage data generated in home country to support approval in the EU, US, or in other regions, common determinants of success include compliance with local regulatory expectations, population representativeness, selection of standard of care, and alignment with previous regulatory precedents.

Manufacturers should evaluate previous regulatory decisions for comparable devices and indications. Understanding what evidence has previously been accepted by local authorities helps ensure that your future clinical strategies align with regulatory precedent.

Although every submission is evaluated individually, some evidence packages are consistently more transferable across jurisdictions than others.

This type of evidence can include:

• studies designed according to internationally recognized standards with guidelines aligned with local regulations.
• clinical strategies that have been designed and supported by early interactions with regulatory authorities, allowing discussion and alignment of study design elements before trial execution.
• data generated in multi-regional studies with clinical sites in several countries that support extrapolation across countries.
• clinical strategies with relevant endpoints that are clinically meaningful and aligned with what local regulators, clinical guidelines, physicians, and healthcare systems consider important.

Regulators can also request bridging data or additional justification in situations when:

• study designs do not reflect local regulatory expectations or established regulatory precedents.
• applicability of the observed benefit-risk profile to the target population has not been adequately demonstrated.
• clinical evidence is based on treatment pathways or standards of care that differ substantially from those used locally.
• comparators, endpoints, follow-up periods, or statistical assumptions are insufficiently justified for the target jurisdiction.

Medtech companies should conduct a formal gap assessment when regional differences exist; a well-supported scientific justification can substantially improve the likelihood of regulatory acceptance.

How Regulatory Evidence Gap Analysis Guides Global Evidence Strategy

Once target-market requirements have been mapped, a formal regulatory evidence gap analysis can help determine how well the existing clinical evidence aligns with expectations in each priority jurisdiction. The analysis assesses the characteristics of the available evidence against local regulatory requirements and clinical practice. This assessment can cover such aspects as study design, patient population, endpoints, comparators, follow-up duration, statistical assumptions, standard of care, and relevant regulatory precedent.

This comparison helps manufacturers determine whether existing data can be leveraged as they are, whether additional scientific justification may be sufficient to support their use, or whether complementary evidence generation is needed. Where gaps remain, manufacturers can incorporate ongoing studies, additional endpoints, real-world evidence, or targeted bridging studies.

Early gap analysis allows manufacturers to address these differences before submission rather than after questions are raised by regulators.

Conclusion

Successful global clinical evidence strategies are rarely developed for one market at a time. They are built with international expansion in mind from the earliest stages of product development.

Medtech companies do not need to create separate evidence packages in every jurisdiction for global expansion. They need an integrated and flexible clinical strategy that balances global efficiency with local regulatory expectations.

A clear outline of where these requirements overlap and where they differ helps medical device manufacturers generate evidence that supports multiple markets, minimizes duplication, reduces development costs, and accelerates patient access worldwide.

How Alira Health Can Help

Alira Health brings regulatory, clinical, market access, and commercialization perspectives into one evidence-planning process. Our approach ensures that evidence generation supports not only regulatory approval, but also clinical adoption and payer decision-making. As a result, our clients can reduce rework, accelerate time to adoption, and improve the likelihood of achieving both coverage and commercial scale in their target markets.

Contact us to for a gap analysis and assess your current clinical, regulatory, and commercial plan against your priority markets.